Opportunistic cytomegalovirus infection in a patient receiving temozolomide for treatment of malignant glioma

Yaman E., Coskun U., Ozturk B., Buyukberber S., Kaya A. O., Coskun Ö., ...Daha Fazla

JOURNAL OF CLINICAL NEUROSCIENCE, cilt.16, sa.4, ss.591-592, 2009 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 16 Sayı: 4
  • Basım Tarihi: 2009
  • Doi Numarası: 10.1016/j.jocn.2008.05.030
  • Dergi Adı: JOURNAL OF CLINICAL NEUROSCIENCE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED)
  • Sayfa Sayıları: ss.591-592
  • Gazi Üniversitesi Adresli: Evet

Özet

Treatment of malignant gliomas has changed substantially over the last few years. An Oral alkylating agent, temozolomide, has become the standard agent for glioma management. Although it is generally well tolerated, it can cause lymphopenia and may lead to opportunistic infections. We report on a patient with malignant glioma who developed opportunistic cytomegalovirus (CMV) pneumonia following the termination of temozolomide therapy. The patient was admitted with acute dyspnea, fever and hypoxia, and she was diagnosed with CMV pneumonitis using a PCR-based CMV-DNA analysis. After treatment with ganciclovir, she recovered dramatically. To our knowledge, although there have been reported cases of Pneumocystis carinii infection associated with temozolomide therapy, there has only been one other case of CMV infection. We also review this report. (C) 2008 Elsevier Ltd. All rights reserved.